|Bid||0.1850 x 2640300|
|Ask||0.1900 x 16362900|
|Day's range||0.1850 - 0.2000|
|52-week range||0.0386 - 0.4850|
|Beta (5Y monthly)||2.86|
|PE ratio (TTM)||N/A|
|Earnings date||16 Aug 2016 - 20 Aug 2016|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.63|
Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 (Entitlement Offer) and concurrent placement that was announced on 17 March 2021 (Concurrent Placement) which collectively raised approximately A$22.9 million.
Bionomics Limited ( ASX:BNO ) shareholders might be concerned after seeing the share price drop 15% in the last week...
Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a global, clinical stage biopharmaceutical company, today announced positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210. BNC210 is a novel, negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor in development for the treatment of anxiety and stressor-related disorders, and in November 2019 was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of Post-Traumatic Stress Disorder (PTSD).